Diana Biscoe, Rosie Finlayson, Andrew Christopher, ‘Pay-for-delay Arrangements in the Pharmaceutical Industry: How Will They Be Treated under Australian Competition Law?’ (2023) 31(2) Australian Journal of Competition and Consumer Law 111

Sven Gallasch ‘Pay for delay 2.0: Anticompetitive early generic entry agreements in the Australian pharmaceutical sector’ (2023) 30(1) Competition and Consumer Law Journal 44

Brent Fisse, ‘ACCC Guidelines on repeal of section 51(3) could not and do not resolve need for competitor supply/acquisition exception to cartel prohibitions under CCA’ (July 2020)

Arlen Duke, ‘The Repeal of Section 51(3) of the Competition and Consumer Act: A Mistake in Need of Correction’ (2020) 43(1) UNSW Law Journal 250

Arlen Duke and Rhonda L Smith, ‘Protecting Profits Post-Patent Expiry: ACCC v Pfizer, Patents and Competition Law’ (2019) 30(1) Australian Intellectual Property Journal 26

Michael O’Bryan, ‘The repeal of s 51(3) of the Competition and Consumer Act 2010 (Cth)’ (2019) 46(9) Brief (Law Society of Western Australia) 20-23

Arlen Duke and Rhonda L Smith, ‘Protecting Profits Post-Patent Expiry: ACCC v Pfizer, Patents and Competition Law’ (2019) 30(1) Australian Intellectual Property Journal 26

Robert French, ‘Intellectual property and competition law: Nothing special?’ (2019) 117 Intellectual Property Forum 54-57

Brent Fisse, ‘Harper Report Implementation Breakdown: Repeal of Section 51(3) of Competition and Consumer Act 2010 (Cth) and Lack of Proposed Supply/Acquisition Agreement Cartel Exception’ (2019) 47 ABLR 127

Michael O’Bryan, ‘The Repeal of s 51(3) of the Competition and Consumer Act 2010 (Cth)’ (LESANZ Breakfast Meeting, 10 April 2019)